Altimmune, Inc.
corporate_fare Company Profile
Altimmune, Inc. (NASDAQ:ALT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for ALT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for ALT spans 10-Q, 8-K, 424B5, S-3MEF.
Recent high-impact activity:
- Altimmune Q3 Loss Widens to $31.6M as MASH Phase 3 Spending Ramps; $494.9M Liquidity
- Altimmune Q3 Loss Widens to $31.6M, Missing Estimates as Trial Costs Climb
- Pemvidutide Cuts Heavy Drinking Days in Phase 2 AUD Trial; FDA Meeting Set for December
- Altimmune Q2 2026: $519M Cash, Phase 3 PERFORMA Launch, and $45.4M Net Loss
- Altimmune Q2 Loss Beats Estimates; FDA Meeting Planned for AUD Program
Financial Snapshot
Short Interest & Short Volume
12.16 days to coverFINRA reported short interest of 42,131,170 shares in ALT as of the October 30, 2026 settlement, a 0.2% decrease from the prior period — about 12.2 days to cover at its recent average daily volume. On November 20, 2026, 54.2% of ALT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.